COMMUNIQUÉS West-GlobeNewswire

FoRx Therapeutics Presents Preclinical Data at ACS Spring 2026, Confirming FORX-428's Potential for Best-in-Class PARG Inhibition
26/03/2026
PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers Preclinical data show high potency across multiple solid tumor cell lines and in vivo models, including those resistant [...]
Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026
26/03/2026
Oslo, 26 March 2026 - The Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 09:00 CEST on 23 April 2026. The General Meeting will be held electronically and all documents related to the [...]
BioPorto announces the Annual Report for 2025
26/03/2026
March 26, 2026 Announcement no. 04 BioPorto announces the Annual Report for 2025 Copenhagen, Denmark, March 26, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or company) (CPH:BIOPOR), today announced [...]
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
26/03/2026
TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based [...]
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
25/03/2026
TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”), a life science company focused on the development of natural, plant-based active [...]
ATI Advisory Releases New Analysis of MSSP ACO Episodes, Highlighting Concentrated Financial Exposure and Opportunity Under LEAD
25/03/2026
ATI released a data brief analyzing 1.19 million MSSP shadow bundles, finding that Medicare ACO spending is concentrated in specific medical conditions and post-acute settings—creating a clear opportunity for [...]
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
25/03/2026
Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced [...]
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
25/03/2026
SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology [...]
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
26/03/2026
Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million) Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3 million) Sales of [...]
XORTX Announces Share Consolidation
25/03/2026
CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
Exicure, Inc. Reports Full Year 2025 Financial Results
25/03/2026
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position : [...]
Exicure, Inc. Reports Full Year 2025 Financial Results
25/03/2026
REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position : [...]
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement
25/03/2026
Reverse Split Expected to Take Effect March 30, 2026 HOUSTON, March 25, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued [...]
SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
25/03/2026
Added top-rated children’s hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in [...]
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
25/03/2026
- FDA Grants IND Clearance for SER-252 - SER-252 Phase 1b Trial Initiated - Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or [...]
Lifeward Successfully Closes on Strategic Partnership with Oramed
25/03/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people [...]
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
25/03/2026
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund [...]
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
25/03/2026
Evaluating Potential to Preserve Muscle Mass Associated with Weight Reduction Announces Preclinical Study Initiation, Patent Filing and Publication of Independent Scientific Research SOLANA BEACH, Calif., March 25, 2026 [...]
BeyondSpring Files 2025 Annual Report on Form 10-K
25/03/2026
FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and [...]

Pages